Premium
Treat‐and‐extend versus every‐other‐month regimens with aflibercept in age‐related macular degeneration
Author(s) -
Haga Akira,
Kawaji Takahiro,
Ideta Ryuichi,
Inomata Yasuya,
Tanihara Hidenobu
Publication year - 2018
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/aos.13607
Subject(s) - aflibercept , medicine , macular degeneration , visual acuity , regimen , ophthalmology , randomized controlled trial , surgery , chemotherapy , bevacizumab
Purpose To compare the 1‐year outcomes of treat‐and‐extend ( TAE ) and every‐other‐month (2M) regimens with intravitreal aflibercept in Japanese wet age‐related macular degeneration (AMD) patients. Methods Prospective, multicenter, randomized clinical trial. The primary outcome measure was the proportion of eyes in which the best‐corrected visual acuity ( BCVA ) was maintained at week 52 [with a loss of <0.3 logarithm of minimum angular of resolution (log MAR ) units]. The secondary outcome measures were the mean change from baseline in the central retinal thickness ( CRT ) and the number of injections. Results Forty‐one patients were enrolled. The mean changes in the BCVA from baseline in the TAE and 2M were −0.32 ± 0.27 and −0.26 ± 0.30 log MAR units (p = 0.46). The TAE group was noninferior to the 2M group in BCVA maintenance. The mean CRT changes from baseline in the TAE and 2M were −161 ± 133 and −157 ± 90 μ m (p = 0.73). The mean number of injections in the TAE and 2M were 7.5 ± 1.2 (range, 7–12) and 8.0 ± 0.0 (p < 0.0001). Conclusion Treat‐and‐extend ( TAE ) regimen with aflibercept improved the BCVA and CRT to the same extent as 2M regimen, with a reduced number of injections.